Klusa Daria, Lohaus Fabian, Furesi Giulia, Rauner Martina, Benešová Martina, Krause Mechthild, Kurth Ina, Peitzsch Claudia
National Center for Tumor Diseases (NCT), Dresden, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.
Front Oncol. 2021 Mar 4;10:627379. doi: 10.3389/fonc.2020.627379. eCollection 2020.
Radiotherapy and surgery are curative treatment options for localized prostate cancer (PCa) with a 5-year survival rate of nearly 100%. Once PCa cells spread into distant organs, such as bone, the overall survival rate of patients drops dramatically. The metastatic cascade and organotropism of PCa cells are regulated by different cellular subtypes, organ microenvironment, and their interactions. This cross-talk leads to pre-metastatic niche formation that releases chemo-attractive factors enforcing the formation of distant metastasis. Biological characteristics of PCa metastasis impacting on metastatic sites, burden, and latency is of clinical relevance. Therefore, the implementation of modern hybrid imaging technologies into clinical routine increased the sensitivity to detect metastases at earlier stages. This enlarged the number of PCa patients diagnosed with a limited number of metastases, summarized as oligometastatic disease. These patients can be treated with androgen deprivation in combination with local-ablative radiotherapy or radiopharmaceuticals directed to metastatic sites. Unfortunately, the number of patients with disease recurrence is high due to the enormous heterogeneity within the oligometastatic patient population and the lack of available biomarkers with predictive potential for metastasis-directed radiotherapy. Another, so far unmet clinical need is the diagnosis of minimal residual disease before onset of clinical manifestation and/or early relapse after initial therapy. Here, monitoring of circulating and disseminating tumor cells in PCa patients during the course of radiotherapy may give us novel insight into how metastatic spread is influenced by radiotherapy and vice versa. In summary, this review critically compares current clinical concepts for metastatic PCa patients and discuss the implementation of recent preclinical findings improving our understanding of metastatic dissemination and radiotherapy resistance into standard of care.
放射治疗和手术是局限性前列腺癌(PCa)的根治性治疗选择,5年生存率近100%。一旦PCa细胞扩散到远处器官,如骨骼,患者的总生存率会急剧下降。PCa细胞的转移级联和器官嗜性受不同细胞亚型、器官微环境及其相互作用的调节。这种相互作用导致转移前生态位的形成,释放化学吸引因子,促使远处转移的形成。影响转移部位、负担和潜伏期的PCa转移生物学特性具有临床相关性。因此,将现代混合成像技术应用于临床常规检查提高了早期检测转移灶的敏感性。这增加了被诊断为转移灶数量有限(总结为寡转移疾病)的PCa患者数量。这些患者可以接受雄激素剥夺治疗,并结合局部消融放疗或针对转移部位的放射性药物。不幸的是,由于寡转移患者群体中存在巨大的异质性,且缺乏对转移导向放疗具有预测潜力的可用生物标志物,疾病复发的患者数量很高。另一个迄今为止尚未满足的临床需求是在临床表现出现之前和/或初始治疗后早期复发时诊断微小残留疾病。在此,在放疗过程中监测PCa患者循环和播散的肿瘤细胞,可能会让我们对放疗如何影响转移扩散以及反之亦然有新的认识。总之,本综述批判性地比较了转移性PCa患者的当前临床概念,并讨论了最近临床前研究结果的应用,这些结果有助于我们将对转移扩散和放疗抗性的理解纳入标准治疗。